Abbvie Revenue 2025
Abbvie Revenue 2025. Abbv earnings date and information. Adjusted diluted eps of $2.31, a decrease of 6.1 percent;
Adjusted diluted eps of $11.11, a decrease of 19.3. Abbvie last announced its quarterly earnings results on may 3rd, 2024.
Abbvie (Abbv) Delivered Earnings And Revenue Surprises Of 2.21% And 2.65%, Respectively, For The Quarter Ended March 2024.
The company's 2023 adjusted diluted eps guidance excludes any.
The Company's Largest Shareholder Is The Vanguard Group, Inc., With Ownership Of 9.6%.
The reported $2.31 earnings per share for the quarter, topping.
Abbvie Revenue 2025 Images References :
And In 2025, Abbvie Expects Rinvoq's And Skyrizi's Combined Sales To Reach $15 Billion, Fiercepharma Reported.
Abbv earnings date and information.
Abbvie Revenue For The Twelve Months Ending March 31, 2024 Was.
Despite losing exclusivity for its flagship immunology medication humira in the u.s.